<DOC>
	<DOCNO>NCT01057407</DOCNO>
	<brief_summary>This multi-center , open-labeled study examine non-inferiority ASP1585 sevelamer hydrochloride chronic kidney disease patient hyperphosphatemia hemodialysis .</brief_summary>
	<brief_title>A Comparative Study ASP1585 Chronic Kidney Disease Patients With Hyperphosphatemia Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Chronic kidney disease patient hemodialysis Hyperphosphatemia Patients phosphate binder phosphate lower drug 28 day longer , , dose change within 28 day Written inform consent Patients gastrointestinal surgery enterectomy Patients severe cardiac disease Patients severe constipation diarrhea Patients history complication malignant tumor Patients uncontrolled hypertension Patients treat parathyroid intervention</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>CKD</keyword>
	<keyword>ASP1585</keyword>
</DOC>